These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30947619)

  • 1. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice.
    Scholte FEM; Spengler JR; Welch SR; Harmon JR; Coleman-McCray JD; Freitas BT; Kainulainen MH; Pegan SD; Nichol ST; Bergeron É; Spiropoulou CF
    Emerg Microbes Infect; 2019; 8(1):575-578. PubMed ID: 30947619
    [No Abstract]   [Full Text] [Related]  

  • 2. Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine.
    Spengler JR; Welch SR; Scholte FEM; Coleman-McCray JD; Harmon JR; Nichol ST; Bergeron É; Spiropoulou CF
    Antiviral Res; 2019 Oct; 170():104573. PubMed ID: 31377243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.
    Garrison AR; Shoemaker CJ; Golden JW; Fitzpatrick CJ; Suschak JJ; Richards MJ; Badger CV; Six CM; Martin JD; Hannaman D; Zivcec M; Bergeron E; Koehler JW; Schmaljohn CS
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005908. PubMed ID: 28922426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral replicon particles protect IFNAR
    Spengler JR; Welch SR; Scholte FEM; Rodriguez SE; Harmon JR; Coleman-McCray JD; Nichol ST; Montgomery JM; Bergeron É; Spiropoulou CF
    Antiviral Res; 2021 Jul; 191():105090. PubMed ID: 34044061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge.
    Zivcec M; Safronetz D; Scott DP; Robertson S; Feldmann H
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006628. PubMed ID: 30011277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
    Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
    J Virol; 2017 May; 91(10):. PubMed ID: 28250124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR-/- Mice Models.
    Aligholipour Farzani T; Földes K; Hanifehnezhad A; Yener Ilce B; Bilge Dagalp S; Amirzadeh Khiabani N; Ergünay K; Alkan F; Karaoglu T; Bodur H; Ozkul A
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30857305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice.
    Kortekaas J; Vloet RP; McAuley AJ; Shen X; Bosch BJ; de Vries L; Moormann RJ; Bente DA
    Vector Borne Zoonotic Dis; 2015 Dec; 15(12):759-64. PubMed ID: 26684523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.
    Dowall SD; Buttigieg KR; Findlay-Wilson SJ; Rayner E; Pearson G; Miloszewska A; Graham VA; Carroll MW; Hewson R
    Hum Vaccin Immunother; 2016; 12(2):519-27. PubMed ID: 26309231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Novel Multi-Epitope Vaccine Against Crimean-Congo Hemorrhagic Fever Virus: An Integrated Reverse Vaccinology, Vaccine Informatics and Biophysics Approach.
    Tahir Ul Qamar M; Ismail S; Ahmad S; Mirza MU; Abbasi SW; Ashfaq UA; Chen LL
    Front Immunol; 2021; 12():669812. PubMed ID: 34220816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain.
    Papa A; Papadimitriou E; Christova I
    Scand J Infect Dis; 2011 Mar; 43(3):225-9. PubMed ID: 21142621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge.
    Leventhal SS; Meade-White K; Rao D; Haddock E; Leung J; Scott D; Archer J; Randall S; Erasmus JH; Feldmann H; Hawman DW
    EBioMedicine; 2022 Aug; 82():104188. PubMed ID: 35907368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model.
    Pavel STI; Yetiskin H; Kalkan A; Ozdarendeli A
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008834. PubMed ID: 33226988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model.
    Buttigieg KR; Dowall SD; Findlay-Wilson S; Miloszewska A; Rayner E; Hewson R; Carroll MW
    PLoS One; 2014; 9(3):e91516. PubMed ID: 24621656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses.
    Dowall SD; Graham VA; Rayner E; Hunter L; Watson R; Taylor I; Rule A; Carroll MW; Hewson R
    PLoS One; 2016; 11(6):e0156637. PubMed ID: 27272940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model.
    Hawman DW; Ahlén G; Appelberg KS; Meade-White K; Hanley PW; Scott D; Monteil V; Devignot S; Okumura A; Weber F; Feldmann H; Sällberg M; Mirazimi A
    Nat Microbiol; 2021 Feb; 6(2):187-195. PubMed ID: 33257849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection.
    Golden JW; Shoemaker CJ; Lindquist ME; Zeng X; Daye SP; Williams JA; Liu J; Coffin KM; Olschner S; Flusin O; Altamura LA; Kuehl KA; Fitzpatrick CJ; Schmaljohn CS; Garrison AR
    Sci Adv; 2019 Jul; 5(7):eaaw9535. PubMed ID: 31309159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice.
    Bereczky S; Lindegren G; Karlberg H; Akerström S; Klingström J; Mirazimi A
    J Gen Virol; 2010 Jun; 91(Pt 6):1473-7. PubMed ID: 20164263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First documentation of human Crimean-Congo hemorrhagic fever, Kenya.
    Dunster L; Dunster M; Ofula V; Beti D; Kazooba-Voskamp F; Burt F; Swanepoel R; DeCock KM
    Emerg Infect Dis; 2002 Sep; 8(9):1005-6. PubMed ID: 12194785
    [No Abstract]   [Full Text] [Related]  

  • 20. Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus.
    Ghiasi SM; Salmanian AH; Chinikar S; Zakeri S
    Clin Vaccine Immunol; 2011 Dec; 18(12):2031-7. PubMed ID: 22012978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.